Literature DB >> 1188178

Anticonvulsant activity of four oxygenated cannabidiol derivatives.

E A Carlini, R Mechoulam, N Lander.   

Abstract

A pharmacological comparison between cannabidiol (CBD) and four CBD derivatives, namely CBD-aldehyde-diacetate (I), 6-oxo-CBD-diacetate (II), 6-hydroxy-CBD-tri-acetate (III), and 9-hydroxy-CBD-triacetate (IV) was carried out in mice. Protection against maximal electroshock convulsions, potentiation of pentobarbital sleeping-time and reduction of spontaneous motor activity were the effects measured. All 5 compounds were equally potent in potentiating barbiturate sleeping time at doses ranging from 6.25 to 100 mg/kg. At 12.5 and 25 mg/kg only CBD and IV were able to decrease significantly the spontaneous motor activity. CBD, II, III and IV were also active in protecting mice against electroconvulsive shock at doses of 100-200 mg/kg, although at the larger dose CBD and compound II were the most efficient. Compound I was toxic, killing about half of the animals within 24 h after injection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1188178

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  12 in total

1.  Seizing an opportunity for the endocannabinoid system.

Authors:  Bradley E Alger
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  Plant-Derived and Endogenous Cannabinoids in Epilepsy.

Authors:  Alberto Verrotti; Miriam Castagnino; Mauro Maccarrone; Filomena Fezza
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

Review 4.  Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

Authors:  João F C Pedrazzi; Frederico R Ferreira; Danyelle Silva-Amaral; Daniel A Lima; Jaime E C Hallak; Antônio W Zuardi; Elaine A Del-Bel; Francisco S Guimarães; Karla C M Costa; Alline C Campos; Ana C S Crippa; José A S Crippa
Journal:  Psychopharmacology (Berl)       Date:  2022-07-29       Impact factor: 4.415

5.  delta 1-Tetrahydrocannabinol-induced circling behavior in rats: a possible measure of psychotomimetic activity?

Authors:  I Nir; H D Veldhuis; J M van Ree
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 6.  Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.

Authors:  Maureen L Petrunich-Rutherford; Michael W Calik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.

Authors:  Paula Morales; Patricia H Reggio; Nadine Jagerovic
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

Review 8.  Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease.

Authors:  Felipe Patricio; Alan Axel Morales-Andrade; Aleidy Patricio-Martínez; Ilhuicamina Daniel Limón
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

Review 9.  Cannabinoids in health and disease.

Authors:  Natalya M Kogan; Raphael Mechoulam
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

Review 10.  Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.

Authors:  István Ujváry; Lumír Hanuš
Journal:  Cannabis Cannabinoid Res       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.